CoChat

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit

Open access
Triulzi, Tiziana, Regondi, Viola, De Cecco, Loris, Cappelletti, Maria Rosa, Di Modica, Martina, Paolini, Biagio, Lollini, Pier Luigi, Di Cosimo, Serena, Sfondrini, Lucia, Generali, Daniele, Tagliabue, Elda · 2018 · British Journal of Cancer

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Optimising the selection of HER2-targeted regimens by identifying subsets of HER2-positive breast cancer (BC) patients who need more or less therapy remains challenging. We analysed BC samples before and after treatment with 1 cycle of trastuzumab according to the response to trastuzumab. METHODS: Gene expression profiles of pre- and post-treatment tumour samples from 17 HER2-positive BC patients were analysed on the Illumina platform. Tumour-associated immune pathways and blood counts were analysed with regard to the response to trastuzumab. HER2-positive murine models with differential responses to trastuzumab were used to reproduce and better characterise these data. RESULTS: Patients who responded to single-agent trastuzumab had basal tumour biopsies that were enriched in immune pathways, particularly the MHC-II metagene. One cycle of trastuzumab modulated the expression levels of MHC-II genes, which increased in patients who had a complete response on treatment with trastuzumab and chemotherapy. Trastuzumab increased the MHC-II-positive cell population, primarily macrophages, only in the tumour microenvironment of responsive mice. In patients who benefited from complete trastuzumab therapy and in mice that harboured responsive tumours circulating neutrophil levels declined, but this cell subset rose in nonresponsive tumours. CONCLUSIONS: Short treatment with trastuzumab induces local and systemic immunomodulation that is associated with clinical outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-018-0318-0

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Molecular features of HER2+ BC biopsies associated with trastuzumab cytotoxic and cytostatic activity. a Scheme of the number of tumours in each group. C+: responders (patients who experienced a reduction of at least 20% in tumour volume); C−: non-responders. K+: responders (patients who experienced a reduction of at least 50% in the number of Ki67-positive cells in their tumours after treatment with trastuzumab); K−: non-responders. b Averaged normalised enrichment score (NES) of pathways in each cluster significantly enriched (FDR <10%) in each comparison. Clusters were visualised using Cytoscape and labelled manually. Grey squares indicate no significant enrichment. c GSEA enrichment plots of PD1 gene set in C+ compared with C− tumours. NES, normalised enrichment score. d Expression of MHC-II metagene according to tumour partition based on C and K responses. p-value by unpaired t-test
Fig. 1 Molecular features of HER2+ BC biopsies associated with trastuzumab cytotoxic and cytostatic activity. a Scheme of the number of tumours in each group. C+: responders (patients who experienced a reduction of at least 20% in tumour volume); C−: non-responders. K+: responders (patients who experienced a reduction of at least 50% in the number of Ki67-positive cells in their tumours after treatment with trastuzumab); K−: non-responders. b Averaged normalised enrichment score (NES) of pathways in each cluster significantly enriched (FDR <10%) in each comparison. Clusters were visualised using Cytoscape and labelled manually. Grey squares indicate no significant enrichment. c GSEA enrichment plots of PD1 gene set in C+ compared with C− tumours. NES, normalised enrichment score. d Expression of MHC-II metagene according to tumour partition based on C and K responses. p-value by unpaired t-testCC BY · PubMed Central
Fig. 2 Modification of immune metagene expression by trastuzumab a Correlation between MHC-II expression at baseline and its modulation by trastuzumab (fold-change) in all cases of the TRUP cohort. Spearman coefficients and relative p-values are shown. b–d Modulation of MHC-II (b), LCK (c), and HCK (d) metagene expression in post-treatment vs pretreatment biopsies according to response to trastuzumab-based chemotherapy as evaluated at surgery. Fold-change in C+K+ tumours is also shown. p-values by unpaired t-test
Fig. 2 Modification of immune metagene expression by trastuzumab a Correlation between MHC-II expression at baseline and its modulation by trastuzumab (fold-change) in all cases of the TRUP cohort. Spearman coefficients and relative p-values are shown. b–d Modulation of MHC-II (b), LCK (c), and HCK (d) metagene expression in post-treatment vs pretreatment biopsies according to response to trastuzumab-based chemotherapy as evaluated at surgery. Fold-change in C+K+ tumours is also shown. p-values by unpaired t-testCC BY · PubMed Central
Fig. 3 Expression of MHC-II in TRUP tumours. a Representative IHC images of MHC-II expression in FFPE tumour biopsies of the TRUP cohort. Scale bars: 50 μm. b Change in M1 macrophage fraction as evaluated using the CIBERSORT tool on treatment with trastuzumab in cases of the TRUP cohort according to response to trastuzumab-based chemotherapy, as evaluated at surgery. Fold-change in C+K+ tumours is also shown. p-values by unpaired t-test. c Correlation between changes in MHC-II and M1 (fold-change) induced by trastuzumab in all cases of the TRUP cohort. Spearman coefficients and relative p-values are shown
Fig. 3 Expression of MHC-II in TRUP tumours. a Representative IHC images of MHC-II expression in FFPE tumour biopsies of the TRUP cohort. Scale bars: 50 μm. b Change in M1 macrophage fraction as evaluated using the CIBERSORT tool on treatment with trastuzumab in cases of the TRUP cohort according to response to trastuzumab-based chemotherapy, as evaluated at surgery. Fold-change in C+K+ tumours is also shown. p-values by unpaired t-test. c Correlation between changes in MHC-II and M1 (fold-change) induced by trastuzumab in all cases of the TRUP cohort. Spearman coefficients and relative p-values are shownCC BY · PubMed Central
Fig. 4 Modulation of MHC-II-positive cells on trastuzumab treatment in HER2+ murine models. a, b Representative dot plots of MHC-II-positive cells in MI6 (a) and WTHER2 (b) tumours and frequency of MHC-II-positive cells in mice treated or not (NT) with trastuzumab by flow cytometry. p-values by unpaired t-test
Fig. 4 Modulation of MHC-II-positive cells on trastuzumab treatment in HER2+ murine models. a, b Representative dot plots of MHC-II-positive cells in MI6 (a) and WTHER2 (b) tumours and frequency of MHC-II-positive cells in mice treated or not (NT) with trastuzumab by flow cytometry. p-values by unpaired t-testCC BY · PubMed Central
Fig. 5 Modulation of circulating immune cells on trastuzumab treatment. a, b Modulation of leukocyte (a) and neutrophil (b) levels by trastuzumab in the blood of TRUP patients according to response to treatment. The ratio of cell counts between the time of Tru-cut biopsy and baseline in each patient is shown. p-values by unpaired t-test. c Percentage of neutrophils by flow cytometry, defined as Ly6G+F4/80− cells gated on CD11b+ cells, in the spleen of mice bearing MI6 tumours and treated or not (NT) with trastuzumab. p-value by unpaired t-test
Fig. 5 Modulation of circulating immune cells on trastuzumab treatment. a, b Modulation of leukocyte (a) and neutrophil (b) levels by trastuzumab in the blood of TRUP patients according to response to treatment. The ratio of cell counts between the time of Tru-cut biopsy and baseline in each patient is shown. p-values by unpaired t-test. c Percentage of neutrophils by flow cytometry, defined as Ly6G+F4/80− cells gated on CD11b+ cells, in the spleen of mice bearing MI6 tumours and treated or not (NT) with trastuzumab. p-value by unpaired t-testCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 94

Metadata

Authors
Triulzi, T., Regondi, V., De Cecco, L., Cappelletti, M. R., Di Modica, M., Paolini, B., Lollini, P. L., Di Cosimo, S., Sfondrini, L., Generali, D., & Tagliabue, E.
Affiliations
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • Azienda Socio Sanitaria Territoriale di Cremona (IT)
  • University of Bologna (IT)
  • University of Milan (IT)
  • University of Trieste (IT)
Corresponding author
Tagliabue, Elda
Venue
British Journal of Cancer
Published
2018-11-27
Volume
119
Issue
12
Pages
1487-1494
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2900717255
Cited by
94
References
36
Citations by year
2026: 3 · 2025: 6 · 2024: 8 · 2023: 7 · 2022: 9 · 2021: 16 · 2020: 44 · 2019: 1
FWCI
5.72
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • British Journal of Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, cc-by)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
Funders
Associazione Italiana per la Ricerca sul Cancro
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
trastuzumab, HER2-positive breast cancer, immunomodulation, MHC class II, tumor microenvironment, macrophages, neutrophils, treatment response prediction, gene expression profiling
MeSH terms
Trastuzumab, Antineoplastic Agents, Immunological, Animals, Breast Neoplasms, Female, Genes, MHC Class II, Humans, Immunologic Factors, Erb-b2 Receptor Tyrosine Kinases, Ki-67 Antigen, Mice, Tumor Microenvironment, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit. https://app.cochat.ai/papers/10.1038/s41416-018-0318-0
The paper
Triulzi, T., Regondi, V., De Cecco, L., Cappelletti, M. R., Di Modica, M., Paolini, B., Lollini, P. L., Di Cosimo, S., Sfondrini, L., Generali, D., & Tagliabue, E. (2018). Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit. British Journal of Cancer. https://doi.org/10.1038/s41416-018-0318-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.